Key result
Elevated pre-PCI macrophage migration inhibitory factor levels independently predicted the post-procedural no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
Why the study?
It was unknown whether Macrophage Migration Inhibitory Factor (MIF) levels anticipate no-reflow among STEMI patients.
Do Macrophage Migration Inhibitory Factor (MIF) levels predict no-reflow in STEMI patients treated with primary PCI?
Cohort (n=120)
Yes
Do Macrophage Migration Inhibitory Factor (MIF) levels predict no-reflow in STEMI patients treated with primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated MIF may aid no-reflow risk stratification in STEMI; hypothesis-generating and requires validation before clinical adoption.
To elucidate whether Macrophage Migration Inhibitory Factor (MIF) levels anticipate no-reflow among ST-segment Elevation Myocardial Infarction (STEMI) patients. We enrolled 120 STEMI individuals given treatment with initial PCI. Assessment of the ST-segment dynamics was performed with serial 12-lead ECGs obtained before and after primary PCI within 1-2 hours at 50 mm/sec. In the case of impaired microcirculatory perfusion, the dynamics of ST-segment elevation resolution (STR) remain equal to 70%
No takes yet. Share an insight, caveat, or question.
Storozhenko et al. (2021) conducted a cohort in ST-segment Elevation Myocardial Infarction (STEMI) (n=120). Elevated pre-PCI Macrophage Migration Inhibitory Factor (MIF) levels vs. Lower MIF levels was evaluated on Post-PCI no-reflow phenomenon (OR 1.1, 95% CI 1.0-1.2, p=0.036). Elevated pre-PCI macrophage migration inhibitory factor levels independently predicted the post-procedural no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: